+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis



Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis



Journal of Rheumatology 43(2): 343-349



To evaluate the effect of brodalumab on psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory (PSI) in patients with psoriatic arthritis (PsA). This prespecified analysis of a phase II study (NCT01516957) evaluated patients with active PsA and psoriasis-affected body surface area ≥ 3%, randomized to brodalumab (140 or 280 mg) or placebo every 2 weeks (Q2W) for 12 weeks with loading dose at Week 1. At Week 12, patients entering an open-label extension received brodalumab 280 mg Q2W. The PSI measures 8 psoriasis signs and symptoms: itch, redness, scaling, burning, stinging, cracking, flaking, and pain. PSI response is defined as total PSI ≤ 8 (range 0-32), each item ≤ 1 (range 0-4). PSI scores were assessed at weeks 12 and 24. There were 107 eligible patients. At Week 12, mean improvement in PSI scores was 7.8, 11.2, and 1.5 in brodalumab 140 mg, 280 mg, and placebo groups, respectively; by Week 24, improvement was 10.2, 12.4, and 11.7. At Week 12, 75.0%, 81.8%, and 16.7% of patients receiving brodalumab 140 mg, 280 mg, and placebo, respectively, achieved PSI response; improvement was sustained through Week 24, when 83.9% of prior placebo recipients achieved response. At Week 12, 25.0%, 36.4%, and 2.8% of patients receiving brodalumab 140 mg, 280 mg, and placebo, respectively, achieved PSI 0. Percentages improved through Week 24: 40.0% brodalumab 140 mg, 42.9% brodalumab 280 mg, and 48.4% placebo. Significantly more brodalumab-treated patients with PsA achieved patient-reported improvements in psoriasis signs and symptoms than did those receiving placebo. Improvements were comparable between brodalumab groups.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058072847

Download citation: RISBibTeXText

PMID: 26773108

DOI: 10.3899/jrheum.150182


Related references

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. British Journal of Dermatology 170(3): 705-715, 2014

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology 33(5): 886-892, 2019

AB0741Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique: Diagnostic Value for Detection of Subclinical Signs of Musculoskeletal Inflammation in Psoriasis?. Annals of the Rheumatic Diseases 75(Suppl 2): 1158.1-1158, 2016

Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis. Arthritis Care and Research 67(12): 1750-1756, 2015

Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. ImmunoTherapy 7(4): 323-333, 2015

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Journal of the European Academy of Dermatology and Venereology 33(2): 340-354, 2019

Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey. American Journal of Clinical Dermatology 9(2): 111-117, 2008

AB0755Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis. Annals of the Rheumatic Diseases 73(Suppl 2): 1054.1-1054, 2014

Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Archives of Dermatological Research 311(5): 351-360, 2019

Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross-sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires. Rheumatology International 36(2): 207-212, 2016

Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy 15(6): 883-893, 2015

Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Journal of Dermatology 38(4): 321-334, 2011

Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only. American Journal of Clinical Dermatology 9(2): 111-117, 2008

Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatology 149(10): 1180-1185, 2013

Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance. Journal of Dermatology 43(7): 767-778, 2016